Why is Alvotech stock rallying today?

Alvotech shares rose 6.2% pre-open after resubmitting BLAs to the FDA for AVT05 and AVT06, reviving expectations for regulatory approval within a six-month review window. The filings follow the company’s response to FDA manufacturing observations at its Reykjavik facility and support plans to launch five U.S. products by year-end through its Teva partnership. The stock has also been under pressure near 52-week lows, making the catalyst more meaningful for investor sentiment.

Analysis

The market is likely reacting less to the filing itself than to the removal of a binary overhang that had been compressing terminal value. For a biosimilar platform, the first re-rating usually comes when investors stop assigning a near-zero probability to manufacturing remediation failure; that matters because the equity can gap well before any approval decision if the review clock is now credible. The move also signals that the stock was crowded on the wrong side of an execution reset, so a modest amount of good news can force a sharp short-covering and momentum chase.

The second-order winner is Teva, but the benefit is asymmetric and mostly in sentiment/optionality rather than immediate P&L. A cleaner regulatory path for partnered biosimilars improves Teva’s perception as a commercialization platform for late-cycle branded erosion, which can modestly support multiple stability even if the direct dollar contribution is small near term. Less obvious: if Alvotech’s manufacturing remediation is accepted, contract manufacturing and supply-chain partners also de-risk, which can accelerate the rest of the pipeline by reducing the probability that future programs inherit the same facility discount.

The key risk is that this is still a six-month catalyst, not a completed de-risking. FDA review can pause for quality questions, and the market is probably extrapolating a clean approval sequence that is not guaranteed; any further information request would likely unwind a good portion of the move because the stock’s recent lows imply a fragile holder base. Contrarian read: the rally may be underpowered if investors are only valuing one or two products, because the real option is in proving the manufacturing flywheel and unlocking a broader biosimilar slate over 12-24 months, not just this round of filings.

Key Decisions for Investors

• Long ALVOW for a 3-6 month catalyst window; use tight downside control because the stock remains highly sensitive to any FDA process setback. Favor entering on intraday weakness after the initial gap, with a target of a partial retrace toward consensus fair value if the review stays on track.
• Buy call spreads in ALVOW rather than outright equity for the next FDA checkpoint; the thesis is volatility compression plus a binary uplift over 90-180 days, with defined loss if the process stalls.
• For relative value, long ALVOW / short a basket of biosimilar laggards with similar execution risk but no near-term catalyst. The edge is that Alvotech now has a concrete path to re-rating while peers remain stuck in wait-and-see mode.
• Small tactical long TEVA as a partner-beneficiary trade, but size it as a sentiment trade, not a fundamental rerating story. The better risk/reward is to hold through the next manufacturing/regulatory updates and trim if the market starts pricing commercial perfection too early.
• Avoid chasing the open; if the stock holds gains after the first 1-2 sessions, add only on confirmation that volume is not just short-covering. If the FDA timeline slips or the market broadens to risk-off, this name can give back a large portion of the move quickly.